Nationwide Fund Advisors increased its holdings in Aduro Biotech, Inc. (NASDAQ:ADRO) by 12.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,112 shares of the biotechnology company’s stock after buying an additional 2,567 shares during the period. Nationwide Fund Advisors’ holdings in Aduro Biotech were worth $263,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. JPMorgan Chase & Co. raised its stake in Aduro Biotech by 283.7% in the second quarter. JPMorgan Chase & Co. now owns 372,348 shares of the biotechnology company’s stock worth $4,244,000 after buying an additional 275,295 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in Aduro Biotech by 5.7% in the first quarter. Schwab Charles Investment Management Inc. now owns 145,112 shares of the biotechnology company’s stock worth $1,560,000 after buying an additional 7,812 shares in the last quarter. Vanguard Group Inc. raised its stake in Aduro Biotech by 2.1% in the first quarter. Vanguard Group Inc. now owns 2,382,916 shares of the biotechnology company’s stock worth $25,617,000 after buying an additional 48,840 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Aduro Biotech by 3.8% in the first quarter. Bank of New York Mellon Corp now owns 148,166 shares of the biotechnology company’s stock worth $1,593,000 after buying an additional 5,470 shares in the last quarter. Finally, Russell Investments Group Ltd. bought a new position in Aduro Biotech in the second quarter worth approximately $408,000. 34.01% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Nationwide Fund Advisors Acquires 2,567 Shares of Aduro Biotech, Inc. (ADRO)” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/11/12/nationwide-fund-advisors-acquires-2567-shares-of-aduro-biotech-inc-adro.html.

In other news, CEO Stephen T. Isaacs sold 40,000 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $10.78, for a total transaction of $431,200.00. Following the sale, the chief executive officer now directly owns 213,921 shares of the company’s stock, valued at $2,306,068.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jennifer Lew sold 6,600 shares of the business’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $11.70, for a total transaction of $77,220.00. Following the sale, the insider now directly owns 49,195 shares in the company, valued at $575,581.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 173,745 shares of company stock worth $1,782,876. Insiders own 6.60% of the company’s stock.

A number of brokerages recently commented on ADRO. HC Wainwright set a $18.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a research note on Wednesday, November 1st. BidaskClub downgraded shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Zacks Investment Research downgraded shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Canaccord Genuity set a $30.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, William Blair reissued an “outperform” rating on shares of Aduro Biotech in a research note on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $19.14.

Aduro Biotech, Inc. (NASDAQ ADRO) opened at $7.95 on Friday. Aduro Biotech, Inc. has a 12-month low of $6.01 and a 12-month high of $15.52.

Aduro Biotech (NASDAQ:ADRO) last issued its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). The business had revenue of $3.79 million for the quarter, compared to analyst estimates of $4.04 million. Aduro Biotech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.54) earnings per share. research analysts anticipate that Aduro Biotech, Inc. will post -1.28 EPS for the current year.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Institutional Ownership by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.